This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
A team of scientists from the universities of Glasgow and Tel Aviv has developed a groundbreaking method to transform the brain parasite Toxoplasma gondii into a potential vehicle for delivering therapeutic treatments directly to brain cells.
A team of scientists—led by Yamin Zhang, Ph.D., at Northwestern University—has developed novel technology with the potential to change the future of drugdelivery. and Colin Franz, MD, Ph.D., at Shirley Ryan AbilityLab and John Rogers, Ph.D.,
Scientists have established a new method to image proteins that could lead to new discoveries in disease through biological tissue and cell analysis and the development of new biomaterials that can be used for the next generation of drugdeliverysystems and medical devices.
In a promising advancement, scientists from the University of North Carolina at Chapel Hill and Emory University have developed a novel drugdeliverysystem using synthetic amyloid beta (AÎ) peptides.
Behfar, senior scientist at VTT, in the news release. Aayush Jaiswal, research scientist at VTT said, “Ours is the first nanocellulose-based ECG patch with no plastic additives. Bio-based substrates like cellulose e-skin are promising alternatives to fossil-based ones.
Certain areas where this technology is working hand-in-hand with healthcare are: Unsustainable healthcare systems into sustainable ones Equalizing the relationship between medical professionals and patient Provide cheaper, faster and more effective solutions for diseases. Drug Development. Management & Administration.
Clinical trials are the backbone of medical research, paving the way for new treatments, drugs, and therapeutic procedures that can potentially revolutionize healthcare. For instance, if the trial involves a novel drug-deliverysystem, the DSMB might include a pharmaceutical scientist.
Christine lynn lanning, Distinguished Scientist, Device Area Leader, Merck. Deep S Bhattacharya, Senior Scientist, Drug Product Development and Design, Pfizer. Engage in panel discussions with industry leaders to navigate the accelerating digital health landscape for combination products and drugdeliverysystems.
Over the last decade, one of the major challenges faced by pharmaceutical companies across the globe is low drug solubility. In fact, it has been observed that around 40% of the pharmaceutical drugs approved by regulatory organizations exhibit poor bioavailability / solubility.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content